Skip to content

Study · Not a test of the peptide alone · 2014

1 result

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E

Diabetes research and clinical practice14 Jan 2014Cited by 81 (Europe PMC)

PMID24485345 (opens in a new tab)DOI10.1016/j.diabres.2014.01.010 (opens in a new tab)PepBankPUB-24485345
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) did not change the risk of pancreatitis versus comparators.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, semaglutide among them, did not raise pancreatitis risk compared with comparators.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatitis risk
    Study

    n = 14,972

    Comparator
    Placebo or active drugs
    Outcome group
    Adverse events · Gastrointestinal

    Measurements

    MH-OR
    1.01 ratio
    pancreatitis, GLP-1 RA vs comparators

    Source sentences

    Summary
    The overall risk of pancreatitis was not different between GLP-1RA and comparators (MH-OR: 1.01[0.37; 2.76]; p = 0.99).
    1 context sentence
    Summary · context
    (i) randomized trials, (ii) duration ≥12 weeks; (iii) on type 2 diabetes; and (iv) comparison of GLP-1RA with placebo or active drugs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 34 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:25 UTC. The status did not change between them.

    Study results updated

  2. Version 33

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Versions 3 to 32

    21 Oct 2026, 17:06 UTC

    The same notice was added 30 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.